Match!
Roger S. Blumenthal
Johns Hopkins University School of Medicine
919Publications
80H-index
25.4kCitations
Publications 919
Newest
#1Erin Donnelly Michos (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 41
#2John Wikstrand (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 64
Last.Roger S. Blumenthal (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 80
view all 3 authors...
Lipid Management to Prevent CVD Management of serum cholesterol level is a central objective in preventing cardiovascular events. Current guidelines recommend calculation of cardiovascular risk, wi...
Source
#1Kelly Arps (Johns Hopkins University)H-Index: 1
#2Mahmoud Al Rifai (Johns Hopkins University)H-Index: 10
Last.John Wikstrand (Johns Hopkins University)H-Index: 64
view all 10 authors...
Low-dose rivaroxaban was effective in secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in the COMPASS trial. There is no established role, however, for oral anticoagulants in primary prevention. We evaluated whether coronary artery calcium (CAC) scoring identifies a high-risk primary prevention adult population who may benefit from low-dose rivaroxaban to prevent ASCVD events. We modeled expected outcomes of low-dose rivaroxaban in 5,196 Multiethnic Study of Atherosclerosis...
Source
#1Donna K. Arnett (UK: University of Kentucky)H-Index: 85
#2Amit Khera (UTSW: University of Texas Southwestern Medical Center)H-Index: 52
Last.Roger S. Blumenthal (Johns Hopkins University)H-Index: 80
view all 3 authors...
1 CitationsSource
#1Donna K. ArnettH-Index: 85
#2Roger S. BlumenthalH-Index: 80
Last.Boback ZiaeianH-Index: 16
view all 18 authors...
Author(s): Arnett, Donna K; Blumenthal, Roger S; Albert, Michelle A; Buroker, Andrew B; Goldberger, Zachary D; Hahn, Ellen J; Himmelfarb, Cheryl Dennison; Khera, Amit; Lloyd-Jones, Donald; McEvoy, J William; Michos, Erin D; Miedema, Michael D; Munoz, Daniel; Jr, Smith Sidney C; Virani, Salim S; Sr, Williams Kim A; Yeboah, Joseph; Ziaeian, Boback
Source
#1Vincent A. Pallazola (Johns Hopkins University)H-Index: 1
#2Dorothy M. Davis (Johns Hopkins University)
Last.Francine K. Welty (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 37
view all 11 authors...
Abstract Despite continued advances in health care, the cardiovascular disease (CVD) mortality rate has plateaued in recent years and appears to be trending upward. Poor diet is a leading cause of obesity and type 2 diabetes mellitus, which are leading contributors to CVD morbidity and mortality. Although dietary modification is a cornerstone of CVD prevention, implementation in clinical practice is limited by inadequate formal training in nutrition science. In this report, we review the individ...
Source
#1Jon T. Giles (Columbia University)H-Index: 35
#2Mary Chester M. Wasko (TU: Temple University)H-Index: 27
Last.Joan M. Bathon (Columbia University)H-Index: 56
view all 10 authors...
1 CitationsSource
#1Pratik B. Sandesara (Emory University)H-Index: 11
#2Anurag Mehta (Emory University)H-Index: 5
Last.Laurence S. Sperling (Emory University)H-Index: 34
view all 9 authors...
Abstract Background and aims Individuals with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL are considered high-risk and current guidelines recommend initiating high-intensity statin therapy in this group. We sought to examine the predictive ability of zero CAC in this high-risk group. Methods Multi-Ethnic Study of Atherosclerosis participants without clinical cardiovascular disease and baseline LDL-C ≥190 mg/dL were identified. Cardiovascular risk factors were compared between those wi...
Source
Dr. Mehta and colleagues do an excellent job of emphasizing the importance of preventive cardiovascular medicine training for all cardiology fellows during their training. The goal for all program directors is to address the gap between scientific discovery and implementation of proven preventive
Source
Author(s): Arnett, Donna K; Blumenthal, Roger S; Albert, Michelle A; Buroker, Andrew B; Goldberger, Zachary D; Hahn, Ellen J; Himmelfarb, Cheryl D; Khera, Amit; Lloyd-Jones, Donald; McEvoy, J William; Michos, Erin D; Miedema, Michael D; Munoz, Daniel; Smith, Sidney C; Virani, Salim S; Williams, Kim A; Yeboah, Joseph; Ziaeian, Boback
44 CitationsSource
#1Richard A. Ferraro (Johns Hopkins University)
#2Caitlin M. Nass (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 9
Last.Sudipa Sarkar (Johns Hopkins University)
view all 5 authors...
Abstract The treatment of cardiovascular disease in patients with diabetes has seen a sea change in recent years with the development of novel antihyperglycemic agents. The impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), two medication classes introduced in the United States in the wake of increased scrutiny by the US Food and Drug Administration on cardiovascular disease and antihyperglycemic agents, highlight this progressi...
Source
12345678910